# Tissue Regenix: Operating leverage

- Link: https://www.directorstalkinterviews.com/tissue-regenix-operating-leverage/4121083988
- Published: 2022-09-27T07:47:00+01:00
- Author: Amilia Stone

**Tissue Regenix Group plc **(TRX) is focused on the development and commercialisation
of two proprietary processing technologies for the repair of soft tissue (dCELL)
and bone (BioRinse). It has a broad portfolio of regenerative medicine products 
for the biosurgery, orthopaedics and dental markets. 1H’22 results provided further
evidence of the benefits of TRX’s strategic activities over the past two years, 
with the combination of sales growth and operating efficiencies driving the company
rapidly towards EBITDA- and cashflow-breakeven. Additional efficiencies identified
in San Antonio’s capacity expansion give greater flexibility to the start of Phase
2.

 * **Strategy:** Tissue Regenix is building an international regenerative medicine
   business around its proprietary technology platforms, underpinned by compelling
   clinical outcomes. Phase 1 of its manufacturing capacity expansion programme 
   came on stream in July 2021 to satisfy demand from distribution partners for 
   its innovative products.
 * **Interim results:** 1H’22 results were marginally better than forecast, which
   benefited from the trading update provided in July. Underlying sales rose 27%,
   to $11.84m ($9.43m), and the EDITDA loss was reduced greatly, by 59%, to $0.65m(
   $1.61m). Gross cash at the period-end was $6.17m.
 * **Outlook:** Strong sales growth was seen in all three divisions, and is expected
   to continue through 2H’22. With increased operating efficiencies and close control
   of corporate costs, the sales growth is providing leverage towards profitability,
   and TRX is now expected to become EBITDA-positive during 4Q’22.
 * **Risks:** To some degree, forecasts are dependent on the continued recovery 
   in elective surgeries in the US – so we are mindful of a potential outbreak of
   winter COVID. Also, in the current economic climate, labour shortages within 
   partners and healthcare institutions, and supply chain challenges, may constrain
   growth.
 * **Investment summary:** Tissue Regenix has a broad portfolio of innovative regenerative
   products that are in demand from surgeons. Completion of Phase 1 of its capacity
   expansion programme and reorganisation of the whole facility have led to operating
   efficiencies and comfort of supply to distribution partners. In our opinion, 
   TRX is well-positioned to deliver persistently strong sales growth, which will
   drive margin expansion and highlight the low rating of the shares. An EV/sales
   multiple of 4x 2023E sales generates a valuation of $122m/£110m.

[DOWNLOAD THE FULL REPORT](https://hardmanandco.com/research/corporate-research/operating-leverage/?dm_i=49CL,1EYA0,6NAI95,6JP8J,1#report-download)

Share on:
